71results about How to "High clinical value" patented technology

The invention relates to the field of cell therapy. Specifically, the invention relates to a method for producing a mesenchymal stem cell population, a mesenchymal stem cell population produced by themethod and a culture supernatant thereof, and a pharmaceutical composition comprising such cells or a culture supernatant thereof. The invention also relates to the mesenchymal stem cell population and a culture supernatant thereof, and uses of the mesenchymal stem cell population and the culture supernatant in prevention and treatment of diseases.

The invention relates to the technical field of biology, provides a stem cell transport protection solution and particularly relates to an adipose-derived mesenchymal stem cell transport protection solution suitable for long-distance transport. The stem cell transport protection solution is prepared from 10 to 30 percent DMSO (dimethyl sulfoxide), 50 to 150 mu g / mL streptomycin, a 50 to 80 percentDMEM (Dulbecco modified eagle medium) and 8 to 20 percent HES (hydroxyethyl starch). The adipose-derived mesenchymal stem cell transport protection solution has the advantages that the stability of cells and the activity of the cells may be maintained, and convenience is brought to storage and long-distance transport.

The invention relates to the medical biology field, in particular to an anti-BCMA (B-cell maturation antigen) antibody, an antigen binding fragment thereof, and a chimeric antigen receptor (CAR) containing the anti-BCMA antibody. The invention also relates to a nucleic acid molecule capable of encoding the CAR, a modified immune cell containing the CAR, and a method for preparing the modified immune cell. The invention also relates to the purposes of the CARs and the modified immune cell for preventing and / or treating B-cell related illness states (such as B-cell related and plasma cell related malignant tumors and autoimmune diseases) and a method for preventing and / or treating the B-cell related illness states.

The invention discloses a nucleic acid aptamer for recognizing liver cancer cells, and a screening method and a purpose thereof. The nucleotide sequence of the nucleic acid aptamer comprises the feature sequence part shown as Seq ID No.1. The purpose comprises the purpose of the nucleic acid aptamer to the design and preparation of anti-liver-cancer medicine or detection reagents. The detection reagents comprise enzyme-linked immunosorbent assay, immunoradiometric assay or fluorescence method. The invention also comprises a target preparation and a medicine composition. The target preparationcomprises the nucleic acid aptamer and a medically acceptable carrier or a shaping agent. The medicine composition comprises the nucleic acid aptamer, at least one antitumor medicine and a medically acceptable carrier. Compared with the prior art, the nucleic acid aptamer can be used for specifically recognizing the liver cancer cells; good application prospects are realized.

The invention belongs to the technical field of bio-medicine, and in particular relates to an orlistat nano-microsphere as well as a preparation method and an application thereof in anti-tumor drugs. The orlistat nano-microsphere provided by the invention is prepared by mixing orlistat and a drug-carrying material, wherein the drug-carrying material is polyethylene glycol-polycaprolactone (mPEG-PCL); the mass ratio of the orlistat to the mPEG-PCL is at (1-2) to (3-10); and the molecular weight ratio of mPEG to PCL is at 2000 to 10000 or 2000 to 20000. The polymer nano-microsphere provided by the invention is prepared by loading the orlistat on the nano-material, so that a hydrophobic property of the nano-microsphere is changed; and through the sustained-release property of the microsphere, the microsphere can be used for preparing drugs for resisting tumor diseases; therefore, the nano-microsphere is huge in potential clinical value.

The invention relates to the field of cell therapy. In particular, the present invention relates to modified mesenchymal stem cells and a culture supernatant thereof, and a pharmaceutical compositioncomprising the cells or the culture supernatant thereof. The invention also relates to the use of the modified mesenchymal stem cells and the culture supernatant for treatment of metabolic disorder ina subject (eg, a human) and the use of the modified mesenchymal stem cells in preparation of a medicine for treating the metabolic disorder in the subject (eg, a human). The invention further relatesto a method of treating the metabolic disorder, which comprises the step of administering to the subject in need thereof the modified mesenchymal stem cell or the culture supernatant or the pharmaceutical composition thereof.

The present invention relates to antibodies (particularly humanized antibodies) against hepatitis B surface antigen (HBsAg), nucleic acid molecules encoding the antibodies, methods for preparing the antibodies, and pharmaceutical compositions containing the antibodies. Furthermore, the invention relates to use of the antibodies and the pharmaceutical compositions. The antibodies and pharmaceuticalcompositions are useful for preventing and / or treating HBV infection or hepatitis B infection and related diseases (such as hepatitis B), for neutralizing the virulence of HBV in a subject (such as ahuman), or for reducing serum levels of HBV DNA and / or HBsAg in the subject.

The invention relates to the field of virus and the field of tumor treatment. Concretely, the invention relates to enterovirus type 68 (EV-D68) or a modified form thereof, or a genomic sequence or cDNA sequence comprising the EV-D68 or the modified form of the EV-D68, or nucleic acid molecules of a complementary sequences of the genomic sequence or cDNA sequence, applications in treating tumors for a subject such as a human being, and applications in preparing pharmaceutical compositions for treating the tumors for the subject such as a human being. The invention also relates to a method for treating the tumors. The method includes steps of applying the EV-D68 or the modified form of the EV-D68, or the genomic sequence or cDNA sequence comprising the EV-D68 or the modified form of the EV-D68 or the nucleic acid molecules of the complementary sequences of the genomic sequence or cDNA sequence to the subject who needs the treatment.

The invention relates to an agonist of deacetylase and application thereof, and belongs to the technical field of medicines. The agonist of deacetylase comprises cinnamyl aldehyde, cinnamyl aldehyde structural analogues or cinnamyl aldehyde derivatives, wherein the cinnamyl aldehyde structural analogues comprises phenylpropionaldehyde, phenylacetaldehyde, benzaldehyde, propionaldehyde, acetaldehyde or formaldehyde; the cinnamyl aldehyde derivatives comprise alpha-bromo cinnamaldehyde, alpha-bromo p-chloro cinnamaldehyde, alpha-bromo p-methyl cinnamaldehyde, alpha-methyl cinnamaldehyde, alpha-hexylcinnamaldehyde, 4-chloro cinnamaldehyde, 4-methoxy cinnamaldehyde, 4-fluoro cinnamaldehyde, 2-nitro cinnamaldehyde and p-chloro cinnamaldehyde. The regulation effect of an ARG-NO pathway in a high-glucose induced endothelial cell injury model proves that the agonist of the deacetylase has a protective effect on vascular endothelial injury as an agonist of HDAC.

The invention relates to a method and a system for positioning three-dimensional locations of implants of bones and joints by the aid of structural features. The method includes carrying out earlier-stage processing on image data of bone and joint tissues of human bodies; building two-dimensional projection templates by the aid of projection features of imaging systems, structural feature points of the implants and anatomy feature points of the bones or the joints; solving and building mathematical mapping relations between three-dimensional models and the two-dimensional projection templates;computing and measuring the spatial locations of the implants. Mutual movement features and long-term biomechanics interaction of the three-dimensional models and the two-dimensional projection templates can be tracked by means of long-term follow-up visit. The system comprises modules for implementing various functions of the method. The method and the system have the advantages that accurate data with 6 degrees of freedom can be provided for positioning the surgical implants, and clinical values of domestic and overseas clinical two-dimensional image follow-up visit data can be increased.

The invention provides a medical intelligent mattress sleep monitoring device and method based on a piezoelectric ceramic sensor. The medical intelligent mattress sleep monitoring device includes a piezoelectric ceramic sensor unit, a signal amplification and filtering unit, a microprocessor unit, a communication unit, a USB power supply unit and the like, and is characterized in that the piezoelectric ceramic sensor unit places piezoelectric ceramic sensors. The unit is composed of plurality of sensors. The sensor unit is connected to the signal amplification filter unit through wires. The signal amplification and filtering unit completes the amplification and filtering of original vital sign signals, and the original vital sign signals are sent to the microprocessor unit after being amplified and filtered. The microprocessor unit completes data analysis and processing of the amplified and filtered signals, and finally vital sign signals such as on-bed respiration, heart rate and bodymovement are obtained. According to the medical intelligent mattress sleep monitoring device and method, the monitoring of physiological states such as on-bed heart rate, respiration, body movement is realized by sensing the subtle pressure change of a human body. The medical intelligent mattress sleep monitoring device and method have the characteristics of high accuracy, low cost and the like,are suitable for ordinary consumers, and have a certain market prospect and promotion value.

The invention discloses a hip spica cast orthopedic bed with an adjustable angle, and is applicable to the technical field of medical apparatuses. The bed comprises a support plate and a leg dilating-pushing-supporting mechanism. The leg dilating-pushing-supporting mechanism is installed at the upper side of the support plate, and comprises a support rod detachably connected with a lifting support rack and a leg support cushion arranged at the end away from the support rod. The support rod is horizontally arranged at the top of the support plate with adjustable length. The hip spica cast orthopedic bed with the adjustable angle breaks through the shortcoming that the traditional gyp fixing operation mode is low in efficiency, costly in time and labor, big in human error factor influence, and thoroughly liberates the limitation of human labor resources. One person is enough to complete the treatment of the gyp-supported orthopedic fixing. The hip spica cast orthopedic bed with the adjustable angle has the advantages of being small in size, simple in operation, convenient to dismantle and install and carry, low is production cost, high in clinical value, and therefore worthy to be popularized with full force.

The invention relates to the field of therapeutic antibodies, in particular relates to an anti-programmed cell death-ligand 1 (PD-L1) antibody preparation. The preparation comprises an anti-PD-L1 antibody, a buffer solution and sodium chloride, and added sugar and / or sugar alcohols are absent. The anti-PD-L1 antibody preparation of the invention can maintain antibody stability after long-term storage. In addition, the invention further relates to a use of the anti-PD-L1 antibody preparation in preparing drugs used for the prevention and / or treatment and / or adjuvant treatment and / or diagnosis of tumors or anemia

The invention discloses an establishing method of a rat atrial fibrillation model for simulating characteristics of human diseases. The establishing method comprises the steps that 1) an experimentalrat is raised to 35-45 weeks; 2) for the experimental rat, overload of the rat heart pressure is induced by cervical transverse aortic constriction, and a TAC model rat is formed; 3) after the transverse aortic constriction is carried out on the TAC model rat for 1-2 weeks, small animal ultrasonic treatment is conducted to detect a two-dimensional ultrasonic image and color Doppler flow image of blood vessels of a constriction part; 4) after the TAC model rat is constructed for 6-9 weeks, the inner diameter of the left atrium is detected through small animal ultrasonic treatment, the myocardial metabolism is detected by adopting PET, and the occurrence of atrial remodeling is verified; 5) after the transverse aortic constriction is carried out on the TAC model rat for 6-9 weeks, atrial fibrillation is induced through esophageal electrostimulation, a bioelectrical signal recorder is used for recording an electrocardiogram of the experimental rat body surface, and the rat atrial fibrillation model is obtained through verification. The constructed rat atrial fibrillation model can reflect the characteristics of the clinical human diseases, and the establishing method is simpler, moreconvenient, more economical and more efficient.

The invention discloses a novel direct bilirubin detection kit. The novel direct bilirubin detection kit consists of a reagent R1 and a reagent R2, wherein the reagent R1 consists of a Tris-HCl tartaric acid sodium hydroxide buffer solution, glycerine, dithiothreitol, silver nitrate, methyl isobutyl ketone, triton X-100, Na2-EDTA and oxammonium hydrochloride; the reagent R2 consists of sodium hydrogen phosphate, sodium biphosphate, sodium persulfate, Na2-EDTA and NaCl. All the components are scientifically combined, the accuracy in measuring a sample within 0-400 [mu]mol / L is relatively good, the precision is high, the repeatability is good, the anti-interference ability is strong, the reagents are relatively good in stability, and the novel direct bilirubin detection kit is suitable for a full-automatic biochemical analyzer and has a high clinical use value.

The invention relates to the field of viruses and the field of tumor treatment, in particular to to coxsackievirus B3 (CVB3) and a modification form thereof, a genomic sequence or a cDNA sequence containing the CVB3 or the modification form of the CVB3, or a nucleic acid molecule with a complementary sequence of the genomic sequence or the cDNA sequence, application to treat a tumor of a subject (for example, a human), and application to prepare a pharmaceutical composition for treating the tumor of the subject (such as the human). The invention further relates to a method for treating the tumor, and the method comprises the step that the CVB3 or the modification form of the CVB3, or the genomic sequence or the cDNA sequence containing the CVB3 or the modification form of the CVB3, or thenucleic acid molecular of the complementary sequence of the genomic sequence or the cDNA sequence are applied to the subject needing tumor treating.

The invention belongs to the field of biomedicine, and relates to a compound shown in a formula I, stereoisomers, mixtures or pharmaceutically-acceptable salts of the compound. The invention further relates to an application of the compound, stereoisomers, mixtures or pharmaceutically-acceptable salts thereof in preparing medicines for treating and / or preventing MERS-CoV infection or diseases related to MERS-CoV infection (such as Middle East respiratory syndrome). The formula is as below:(Z-Ile-Glu-X1-Ile-Val-Lys-Lys-Ile-X2-X3-Ile-Glu-Arg-Ala-Ile-Glu-Ala-Gln-Gln-X4-Leu-Leu-Gln-Leu-Thr-Val-Trp-X5-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-B)n(I).

The invention relates to the fields of molecular biologics and disease treatment, in particular to the field of treatment on diseases related to too low activity of PSD-95 and / or PSD-93. Specifically,the invention relates to polypeptide (or variants thereof) for treating diseases related to too low activity of PSD-95 and / or PSD-93 (such as nervous system diseases), a fusion protein with the polypeptide (or variants thereof), and application of the polypeptide (or variants thereof) and the fusion protein. The invention further relates to a medicine composition for treating or alleviating one or more symptoms of diseases related to too low activity of PSD-95 and / or PSD-93 (such as nervous system diseases), wherein the medicine composition comprises the polypeptide (or variants thereof) or the fusion protein.

The invention provides an intelligent calculus detection system through a urinary system X-ray plain film. According to the intelligent calculus detection system through the urinary system X-ray plainfilm, after a patient completes a urinary system X-ray plain film examination item, an image recognition module recognizes a DICOM image matched with the examination item; an image quality judging module performs quality analysis and judgment on the DICOM image; a postoperative judging module performs postoperative change analysis on the DICOM image with qualified quality; an anatomy segmentationmodule performs target organ segmentation on the DICOM image without the postoperative change; a target focus inspection module performs segmentation and positioning on a focus; a structured reporting module integrates all processed data and images, stores the data and the images, and outputs a diagnosis image as the reference for a doctor; and a fully intelligent structured image diagnosis report is automatically generated. The invention also discloses an intelligent calculus detection method through a urinary system X-ray plain film. The system and the method provided by the invention havethe advantages that on the premise of ensuring the quality, the intelligent degree and the normativity are improved; the work efficiency of a community-level doctor is improved; the workload of the doctor is reduced; the work intensity is reduced; and the diagnosis precision is improved.

The invention relates to the fields of biotechnology and disease treatment, and in particular, relates to the field of thrombotic disease treatment. Specifically, the invention relates to a fusion protein comprising an anticoagulant protein and an immunoglobulin Fc structural domain, as well as a medical use of the fusion protein.

Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure ofLine leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

The invention relates to the field of viruses and the field of tumor therapy, in particular to coxsackie B virus 1 (CVB1) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or a cDNA sequence comprising the CVB1 or the modified form thereof or comprising complementary sequences of the genomic sequence or the cDNA sequence, use for treatment of tumors in a subject(such as a person), and use for the preparation of a pharmaceutical composition for treatment of the tumors in the subject (such as a person). The invention further relates to a method for treatment of the tumors. The method comprises the step of applying the CVB1 or the modified form thereof, or the nucleic acid molecule comprising the genomic sequence or the cDNA sequence comprising the CVB1 orthe modified form thereof or comprising the complementary sequences of the genomic sequence or the cDNA sequence to the subject in need.

The invention provides an anticancer intermediate based on PKI-587 and a polyethylene glycol coupled anticancer drug, and preparation methods and application thereof, belonging to the field of treatment of cancers. The anticancer intermediate has a general structural formula as described in the specification, and at least one AC in the general structural formula is the anticancer drug PKI-587. Thepolyethylene glycol coupled anticancer drug has a general structural formula as described in the specification. The above two drugs can realize combined medication of the targeting anticancer drug PKI-587 and a plurality of other anticancer drugs, so toxic response caused by mutual influence and pharmacokinetics of a plurality of other anticancer drugs can be prevented during individual administration of the anticancer drugs, multidrug resistance of cancers is overcome, and synergistic effect is exerted; and the two drugs can be used for preparing anticancer drugs with targeting effect and have critical clinical value and wide market prospects.

The invention provides a novel humanized neutralizing active monoclonal antibody against novel coronavirus and application thereof. The monoclonal antibody with neutralizing activity is separated andscreened from the body of a rehabilitation patient infected with the novel coronavirus, has excellent affinity and specificity for the novel coronavirus (SARS-CoV-2), and can effectively block the combination of the novel coronavirus and receptor protein.

The invention belongs to the technical field of biological medicines, and particularly relates to an Orlistat inclusion compound and a preparation method and application thereof in antineoplastic medicines. The Orlistat inclusion compound disclosed by the invention is an Orlistat-sulfobutylether-beta-cyclodextrin inclusion compound, and the weight ratio of Orlistat to sulfobutylether-beta-cyclodextrin is 1:1-1:25. The invention prepares Orlistat into the inclusion compound, and sulfobutylether-beta-cyclodextrin can increase the solubility of Orlistat, enhance the stability of a medicine, promote medicine absorption and reduce the stimulation of the medicine to the body; as a carrier for Orlistat, sulfobutylether-beta-cyclodextrin can greatly improve the water solubility of guest molecules, so that Orlistat can be adapted to the requirement of liquid preparation and the bioavailability of Orlistat can be increased, and thereby the medicinal value of Orlistat can be better exerted; and the Orlistat inclusion compound can be used in the preparation of antineoplastic medicines, and has great potential clinical value.

The invention discloses a method for screening Down's syndrome through second trimester maternal serum alpha-fetoprotein variants L2 and L3. The method comprises the following steps of collecting a plurality of pregnant women who are definitely diagnosed as DS fetuses through amniotic fluid cell chromosome karyotyping for forming a case set, and randomly selecting a plurality of pregnant women with normal fetus development for forming a comparing set; testing the AFP-L2 and AFP-L3 levels of the serum of the two sets of pregnant women according to an enzyme linked immunosorbent assay method, calculating an optimal critical value and a curve lower area of the AFP-L2 and AFP-L3 screened DS fetus according to an ROC curve; and in testing, and when the AFP-L2 and AFP-L3 levels of the serum of the to-be-tested pregnant woman exceed the preset threshold, determining a fact that the fetus of the to-be-tested pregnant woman is the DS fetus. The method has a beneficial effect that the second trimester maternal serum alpha-fetoprotein variants L2 and L3 realize relatively high sensitivity and specificity in screening the DS fetus and are relatively good markers for screening the DS.

The invention relates to the field of disease treatment and immunology, in particular to an anti-PD-1 antibody or an antigen-binding fragment thereof, a nucleic acid molecule for encoding the anti-PD-1 antibody or the antigen-binding fragment thereof, a method for preparing the anti-PD-1 antibody or the antigen-binding fragment thereof, and a pharmaceutical composition containing the anti-PD-1 antibody or the antigen-binding fragment thereof. The invention further relates to an application of the above antibody ( especially the humanized antibody) or the antigen-binding fragment thereof in preparation of a medicine, wherein the medicine is used for improving immune cell activity and enhancing immune response or is used for preventing and / or treating tumors or infections.